Student Research Committee, Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.
Food Security Research Center, Department of Clinical Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.
Phytother Res. 2023 Apr;37(4):1663-1677. doi: 10.1002/ptr.7778. Epub 2023 Feb 17.
The main aim of the current study was to summarize the findings of available clinical studies to assess nano-curcumin's influence on COVID patients. A comprehensive online search was performed in Scopus, PubMed, ISI Web of Science, and Google Scholar until March 2022 to identify trials that investigated the effects of nano-curcumin in patients with COVID-19. Eight studies comprising 569 patients were included in this review. Compared with placebo, nano-curcumin had no significant effect on C-reactive protein (CRP) and high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6). However, gene expression of IL-6 and gene expression as well as secretion of interleukin-1 beta (IL-1β) significantly decreased following nano-curcumin intervention. Nano-curcumin had beneficial effects on fever, cough, chills, myalgia, and olfactory and taste disturbances. The duration of hospitalization and mortality rate were significantly lower in the nano-curcumin group compared with the control group. Lymphocyte count was significantly increased after curcumin supplementation. Nano-curcumin also had favorable effects on O saturation, sputum, chest pain, wheeze, and dyspnea in patients with COVID-19. No major adverse effects were reported in response to nano-curcumin supplementation. In summary, the results of this systematic review of clinical trials suggested that nano-curcumin supplementation has beneficial effects on inflammation, respiratory function, disease manifestations, and complications in patients with COVID-19 viral infection.
本研究的主要目的是总结现有临床研究的结果，以评估纳米姜黄素对 COVID 患者的影响。在 Scopus、PubMed、ISI Web of Science 和 Google Scholar 上进行了全面的在线搜索，以确定研究纳米姜黄素对 COVID-19 患者影响的试验。本综述纳入了 8 项研究，共 569 例患者。与安慰剂相比，纳米姜黄素对 C 反应蛋白 (CRP) 和高敏 C 反应蛋白 (hs-CRP)、肿瘤坏死因子-α (TNF-α) 和白细胞介素-6 (IL-6) 没有显著影响。然而，纳米姜黄素干预后，IL-6 的基因表达以及白细胞介素-1β (IL-1β) 的基因表达和分泌显著降低。纳米姜黄素对发热、咳嗽、寒战、肌痛以及嗅觉和味觉障碍有有益的影响。与对照组相比，纳米姜黄素组的住院时间和死亡率显著降低。姜黄素补充后淋巴细胞计数显著增加。纳米姜黄素对 COVID-19 患者的氧饱和度、痰液、胸痛、喘息和呼吸困难也有良好的影响。未报告针对纳米姜黄素补充的主要不良反应。总之，这项对临床试验的系统评价结果表明，纳米姜黄素补充对 COVID 病毒感染患者的炎症、呼吸功能、疾病表现和并发症有有益的影响。
